Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2024
Companies covered: 10
Tables & Figures: 100
Countries covered: 19
Pages: 120
Download Free PDF

Non-alcoholic Steatohepatitis Biomarkers Market
Get a free sample of this reportGet a free sample of this report Non-alcoholic Steatohepatitis Biomarkers Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Non-alcoholic Steatohepatitis Biomarkers Market Size
The global non-alcoholic steatohepatitis biomarkers market size was valued at around USD 1.5 billion in 2024 and is estimated to grow at 25.8% CAGR from 2025 to 2034. Non-alcoholic steatohepatitis (NASH) biomarkers have been defined as biological indicators designed to measure, assess, monitor, or predict the progression of NASH along with its response to therapy. NASH is considered a more advanced form of non-alcoholic fatty liver disease (NAFLD).
The rising number of steatohepatitis cases, particularly NASH, is accelerating the growth of the NASH biomarker market. The National Center for Biotechnology Information (NCBI) estimated that the prevalent cases of NAFLD are set to increase by 21%, from 83.1 million in 2015 to 100.9 million in 2030. Furthermore, the number of people diagnosed with NASH is expected to increase by 63% during the same time frame, going from 16.5 million to 27 million. This increase in the disease burden is in large part due to rising obesity levels, diabetes, and metabolic syndrome, all of which are main drivers of NASH. Chronic NASH is often asymptomatic in the early stage and can silently advance to advanced stages of hepatic fibrosis, cirrhosis or even hepatocellular carcinoma, further emphasizing the need for accurate non-invasive biomarker tests.
Additionally, increased screening for chronic liver diseases is greatly augmenting the expansion of the NASH biomarkers market. Numerous health authorities, both domestically and internationally, such as the American Association for the Study of Liver Diseases (AASLD) and the European Association for the Study of the Liver (EASL), have recently updated clinical recommendations focusing on the prompt identification of NAFLD and NASH in pivotal demographics such as people suffering from type 2 diabetes and obesity.
According to secondary research, roughly 50 to 70 percent of individuals diagnosed with type 2 diabetes are believed to have latent NAFLD, with a significant percentage advancing to NASH, underlining the need for routine assessments of liver health. Also, programs such as primary care FibroScan screenings and broader insurance reimbursement policies for fibrosis testing are improving preemptive risk assessment and stratification. These approaches are improving the cognitive processes supporting clinical choices and triggering the use of comprehensive multidisciplinary diagnostic systems designed for NASH identification and surveillance.
Non-alcoholic Steatohepatitis Biomarkers Market Trends
Trump Administration Tariffs
Non-alcoholic Steatohepatitis Biomarkers Market Analysis
Based on type, the market is segmented into serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers, and other types. The global market was valued at USD 1.5 billion in 2024. The serum biomarkers segment dominated the market with the largest revenue share of 32.8% in 2024.
Based on end use, the non-alcoholic steatohepatitis biomarkers market is segmented into pharma and CRO industry, hospitals, diagnostic labs, and academic research institutes. Pharma and CRO industry segment dominated the market with the largest revenue share of USD 42.2% in 2024.
North America: The U.S. non-alcoholic steatohepatitis biomarkers market is projected to grow significantly, from USD 308.8 million in 2024 to USD 2.9 billion by 2034.
Europe: The non-alcoholic steatohepatitis biomarkers market in UK is expected to experience significant and promising growth from 2025 to 2034.
Asia Pacific: Japan non-alcoholic steatohepatitis biomarkers market is anticipated to witness lucrative growth between 2025 – 2034.
Middle East and Africa: The non-alcoholic steatohepatitis biomarkers market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
Non-alcoholic Steatohepatitis Biomarkers Market Share
The market for NASH biomarkers is moderately fragmented, as it includes a mix of specialized biomarker companies and in-vitro diagnostics (IVD) corporations. The top four players, GENFIT, Nordic Bioscience, Siemens Healthineers, and Labcorp, are active in the market and are dominant contributors along with their technologies and alliances. These firms account for approximately 40% of the market share.
The NASH biomarker market is expanding faster than before due to an increase in non-invasive diagnostics with pharmaceutical companies sponsoring targeted therapies. There is also a shift towards the use of integrated AI analytics and multiplexed testing, which is redefining the biomarker space, especially for NASH stratification and therapeutic monitoring.
Non-alcoholic Steatohepatitis Biomarkers Market Companies
Some of the eminent market participants operating in the non-alcoholic steatohepatitis biomarkers industry include:
Non-alcoholic Steatohepatitis Biomarkers Industry News:
The non-alcoholic steatohepatitis biomarkers market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:
Click here to Buy Section of this Report
Market, By Type
Market, By End Use
The above information is provided for the following regions and countries: